EUVIMEDScopri EUVIMED
BeobachtungsstudieOpen access · CC BY 4.0

Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry

Esmé Kamphuis iD, Laura Loman iD, Henry L Han iD, Geertruida L E Romeijn iD, Klaziena Politiek iD, Marie L A Schuttelaar iD

Contact Dermatitis · 2023

DOI: 10.1111/cod.14276 ↗

At a glance

Beobachtungsstudie in Contact Dermatitis, 2023. Written by Esmé Kamphuis and 5 co-authors. Institution: Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Major MEDLINE topics: Dermatitis, Atopic, Dermatitis, Allergic Contact, Eczema. Cited 27 times so far (Crossref); 56 references. The full text is freely available (open access, CC BY 4.0). Funded by: Pfizer, Sanofi.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Real‐world data on the effectiveness of upadacitinib on atopic dermatitis (AD), hand eczema (HE) and HE in the context of AD are limited.

Objectives

To evaluate the effectiveness and safety of upadacitinib on AD and on HE in patients with AD.

Methods

This prospective observational cohort study includes clinical outcomes: Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), Hand Eczema Severity Index (HECSI), Photographic guide; and PROMs: average pruritus and pain Numeric Rating Scale (NRS) score of the past week, Patient‐Oriented Eczema Measure (POEM), Patient‐Oriented Eczema, Dermatology Life Quality Index (DLQI), Atopic Dermatitis Control Tool (ADCT), Patient Global Assessment of Disease (PGAD), Quality Of Life Hand Eczema Questionnaire (QOLHEQ) at baseline, Week 4, and Week 16 of upadacitinib‐treated patients. Adverse events were monitored during each visit.

Results

Thirty‐eight patients were included, of which 32 patients had HE. At Week 16, EASI‐75 was achieved by 50.0%. Absolute cutoff score NRS‐pruritus ≤4 was reached by 62.5%, POEM ≤7 by 37.5%, DLQI ≤5 by 59.4%, ADCT

Subjects

MeSH terms (MEDLINE)

Dermatitis, AtopicDermatitis, Allergic ContactEczemaHumansQuality of LifeProspective StudiesSeverity of Illness IndexPruritusTreatment OutcomeRegistriesHeterocyclic Compounds, 3-Ring

Author keywords

atopic dermatitishand eczemaquality of lifetreatmentupadacitinib

Substances

upadacitinibHeterocyclic Compounds, 3-Ring

Authors and institutions

  • Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Department of Dermatology, Medical Center Leeuwarden, Leeuwarden, The Netherlands.

ORCID profiles: Esmé Kamphuis, Laura Loman, Henry L Han, Geertruida L E Romeijn, Klaziena Politiek, Marie L A Schuttelaar

Funding

  • Pfizer
  • Sanofi

Cite

APA

Kamphuis, E., Loman, L., Han, H. L., Romeijn, G. L. E., Politiek, K., & Schuttelaar, M. L. A. (2023). Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry. Contact Dermatitis. https://doi.org/10.1111/cod.14276

Vancouver

Kamphuis E, Loman L, Han HL, Romeijn GLE, Politiek K, Schuttelaar MLA. Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry. Contact Dermatitis. 2023. doi:10.1111/cod.14276

BibTeX
@article{Kamphuis2023,
  author = {Kamphuis, Esmé and Loman, Laura and Han, Henry L and Romeijn, Geertruida L E and Politiek, Klaziena and Schuttelaar, Marie L A},
  title = {Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry},
  journal = {Contact Dermatitis},
  year = {2023},
  doi = {10.1111/cod.14276}
}
Start for free →